Thursday, September 17, 2009

Juvaris BioTherapeutics Finds $25M

Burlingame-based Juvaris BioTherapeutics announced Thursday that the firm had a first close on a $25M, Series B financing round. The new funding was led by SV Life Sciences and Kleiner Perkins Caufield & Byers. The firm did not say what the size of the first close amounted to. Michael Ross of SVLS will join its board along with the funding. Juvaris is developing adjuvanted vaccines used to improve the immune response of vaccines. The firm said the funding will go to advance its lead compound, which is being targeted at seasonal and pandemic influenza. More information »